Vital Therapies (VTL) has spent years trying to turn plastic tubes into a lifesaving artificial liver. The work has not gone well.

Multiple clinical trials of Vital’s biomedical device called the ELAD System have either been halted prematurely or ended in failure, yet the company keeps at it. Vital’s latest effort — a do-over Phase 3 clinical trial seeking to demonstrate the ELAD System can prolong survival for certain liver failure patients — is nearing completion. Results will be announced in September.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy